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CASE1
AN INTEGRATED PILOT PROJECT UTILIZING AN INTERNAL
HTA PROCESSTO SET MEDICAL AND PAYMENT POLICY IN A
U.S. COMMERCIAL HEALTH PLAN
Watkins J1, Choudhury S1, Sturm L2, Bresnahan B3, Sullivan S3
1Premera Blue Cross, Mountlake Terrace,WA, USA; 2Formulary
Resources, LLC, Issaquah,WA, USA; 3University of Washington,
Seattle,WA, USA
Organization: Premera Blue Cross is a 1.6 million member
regional commercial health plan in the Paciﬁc Northwest.
Problem or Issue Addressed: Need to perform more rigorous
assessments of new medical technologies that present budgetary
and utilization management challenges to our health plan.
Goals: (1) Develop and demonstrate a health technology assess-
ment process for non-pharmacologic new medical technologies,
utilizing plan medical and pharmacy staff, students and contrac-
tors as reviewers, including economic evaluations where data are
available. (2) Apply these assessments to inform development of
speciﬁc medical necessity policies and payment policies and
implement the policy changes at Premera.
Outcomes items used in the decision: Clinical efﬁcacy/
effectiveness, safety, clinical utility and cost-effectiveness/cost-
utility (when sufﬁcient data were available).
Implementation Strategy: A cross-functional strategic planning
group of Premera staff, with advice from University of Wash-
ington faculty, designed a comprehensive process to assess the
value of new medical technologies (medical devices, diagnostics
and novel procedures using existing devices) and apply the
results to policy development. To strengthen our business case,
we conducted a pilot implementation beginning in September
2006. The process involves pipeline surveillance, technology
assessment, review by an independent panel of clinical experts,
policy development and approval by an internal committee,
and policy implementation. Since Premera has a high quality
Pharmacy and Therapeutics Committee that meets the above
description, we utilized this group as an external review com-
mittee, adding one such technology review to each meeting
agenda.
Results: Between September 2006 and January 2008, 8 new
medical technologies were evaluated using this process and one
review was underway at the end of this period. Subjects of the
completed reviews consisted of 2 diagnostic scanning modalities,
2 genetic diagnostic tests, 1 other diagnostic modality, 1 robot-
assisted surgical procedure and 2 image-guided radiotherapy
procedures. Strength of evidence was generally unimpressive
with only 1 case having good evidence, 2 fair and 5 poor. Medical
policies were impacted by 6 reviews: medically necessary without
prior authorization (1), medically necessary with prior authori-
zation (1), investigational with certain exceptions (2) and inves-
tigational without exceptions (2). Payment policies were
established by 2 reviews, in each case determining that the new
procedure would be reimbursed at the same rate as its compara-
tor, since the published studies had failed to demonstrate addi-
tional incremental value.
Lessons Learned: Regional private payers can establish a
rigorous health technology assessment process incorporating
cost-effectiveness analysis, with modest assistance from health
outcomes faculty at a nearby university. These clinical and eco-
nomic evidence assessments are useful to create medical and
payment policies and to reﬁne existing policies. Having a rigor-
ous and transparent process strengthens credibility with provid-
ers and other external stakeholders. In addition, standardizing
processes for assessing value for medical products informs
manufacturers with regard to evidence expectations. Methodol-
ogy developed for reviewing pharmaceuticals can be adapted to
review non-pharmacologic entities, but lack of good quality
evidence from clinical trials is a serious limitation. Medical in-
novations delivering sufﬁcient high-quality evidence require a
comprehensive format to optimize opportunities for scientiﬁc
communication among payers, industry, and academia. Efforts to
establish higher evidence standards for devices and diagnostics
should be encouraged.
CASE 2
DRUG ELUTING STENTS—AN EXAMPLE OFTHETRANSITION
FROM EVIDENCETO POLICYTHROUGHTHE ONTARIO
COMPREHENSIVE APPROACHTOTHE DIFFUSION OF
HEALTHTECHNOLOGIES
Levin L1, Goeree R2
1Ontario Ministry of Health and Long-Term Care,Toronto, ON,
Canada; 2McMaster University, Hamilton, ON, Canada
Organization: Ontario Ministry of Health and Long-Term Care
Program for the Assessment of Technologies in Health Research
Institute.
Problem or Issue Addressed: In 2002, the Ontario Ministry of
Health and Long-Term Care (MOHLTC) was advised that drug
eluting stent (DES) would present a diffusion pressure since
approximately 10,000 stents were being used per year and the
differential cost between bare metal stents (BMS) and DES was
$2200–$3840 per stent. An initial review of the literature by the
Medical Advisory Secretariat (MAS) found that in low-risk
patients the restenosis rates for BMS were 20–30% compared to
0–5% for DES. However, issues of generalisability to the Ontario
health system were raised in the MAS analysis, and a concern
that there would be creep to off-label use in high-risk patients.
Goals: Establish through a pragmatic study whether results pub-
lished from randomized controlled trials on DES are generalis-
able to Ontario and to use this as a basis for long-term funding
decision.
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Outcomes items used in the decision: One year restenosis and
mortality rates according to whether the stents used were bare
metal or drug eluting.
Implementation Strategy: A Conditionally Funded Field Evalua-
tion (CFFE) approach to diffusion was adopted. MOHLTC con-
ditionally provided $12 million annually for DES to be used
exclusively within a pragmatic study conducted by the Program
for the Assessment of Technologies in Health (PATH) Research
Institute with the goal to assess the cost-effectiveness of DES in
the Ontario context. Using a large registry of over 20,000
patients, the PATH Research Institute collected information on
the number and type of stents, rates of revascularization proce-
dures and mortality over a 1 year follow-up period. PATH
reported back the ﬁndings from the study in early 2007 to the
Ontario Health Technology Advisory Committee (OHTAC)
whose advice to MOHLTC was used to make a long-term
funding decision.
Results: It was found that the effectiveness of DES varied widely
across patients with different risk factors and that DES were not
cost-effective in a number of patients. The results of the cost-
effectiveness study, which have not been previously published,
were used by OHTAC to make a recommendation for DES
funding in high risk patients only which, compared to a more
open diffusion policy, resulted in an estimated $22 million annual
savings to the health care system. These results differed from
efﬁcacy data from published RCTs. Reasons for this discrepancy
cannot be provided with certainty but possibilities include differ-
ences in the use of ant-platelet drugs and the use of a more
current bare metal stent.
Lessons Learned: This example of a pragmatic effectiveness study
used to inform decision making demonstrates how an evidence-
based approach to health technology assessment can, and should,
inﬂuence policy decision making when faced with concerns of
generalizability and decision uncertainty.
CASE 3
REVIEWING AND ADAPTING A LOCAL HEALTH
TECHNOLOGY ASSESSMENT PROGRAMTO DEPARTMENTS
WITHIN A CANADIAN HEALTH REGION
Austen L, Poulin P
Calgary Health Region, Calgary, AB, Canada
Organization: The Calgary Health Region.
Problem or Issue Addressed: Many local decision-makers do not
have a consistent and transparent mechanism in place to capture,
integrate, and report on the clinical, administrative, and ﬁnancial
aspects of introducing a new health technology into their local
environment. To address this need, we ﬁrst developed a draft
Local Health Technology Assessment (HTA) program in con-
junction with the Department of Surgery and Surgical Services
within the Calgary Health Region. The project described in the
present report includes piloting, reviewing, and adapting the
Local HTA program to other clinical departments to meet the
needs of these local decision-makers.
Goals: The main objectives of our project were: 1) to develop a
process for reviewing and adapting the Department of Surgery
and Surgical Services Local HTA program to other departments
within the Calgary Health Region, 2) to create ﬁrst and second
revisions of the Local HTA program based on key comments and
recommendations from the stakeholders, and 3) to identify out-
standing issues that need to be addressed by future working
groups. The next phase of the project is a trial of the revised
program during 2008.
Outcomes items used in the decision: Since the overall goal of this
project is to develop a decision-making tool, the outcomes of
interest were: 1) a clear process and documents by which the
program can be fully utilized and evaluated, 2) synthesis of key
comments from participating departments to create a ﬁrst and
second revision of the Local HTA documents, and 3) a list of
outstanding issues that are presently not addressed in the Local
HTA program but that need to be considered.
Implementation Strategy: A six-step process was developed for
reviewing and adapting the Department of Surgery and Surgical
Services Local HTA program to other departments within the
Calgary Health Region. These steps were: 1) development of a
Local HTA Program Review Manual; 2) selection, assessment of
readiness, and education of participating departments; 3) review
of the Local HTA program by individual departments; 4) gath-
ering of feedback and joint review; 5) synthesis of feedback;
and 6) revision of the Local HTA program. Additionally, steps
3–6 were repeated to yield a second revision of the program
documents.
Results: 1) Documents for the Review Manual and ﬁrst and
second revisions of the Local HTA program were produced.
Participants acknowledged that the program has good face valid-
ity and contain the key elements that need to be addressed to
introduce a new technology in a safe, effective and comprehen-
sive manner; 2) A major change in the revised Local HTA
program was the creation of two major pathways for evaluating
new technology: a) Technology Request Pathway, which provides
a rapid method for requesting new technology and ensures that
safety, cost, and legal and contractual issues are considered
(minor change of practice), and b) Local HTA Pathway, which is
used when there are uncertainties about the technology’s clinical
safety and effectiveness and/or its impact on ﬁnances or resources
(signiﬁcant change of practice); and 3) Several issues inad-
equately addressed by the Local HTA program were identiﬁed as
follows: a) Clear guidelines are needed to determine when a
technology needs to be evaluated by the Local HTA Pathway
rather than the Technology Request Pathway; b) Special situa-
tions for technology requests were identiﬁed including urgent/
emergent requests, one-off requests and compassionate requests.
A special process to deal with these requests is being developed
and will include an after-the-fact critical review to ensure
adequate accountability for these requests; c) Approval of many
similar technologies can lead to too many choices and patient
safety issues. There should be an annual “Clinical Expert
Review” of all similar technologies to reduce the numbers of
options available; and d) Often replacement of old technology is
delayed until the situation is critical, then all review processes are
skipped. A process is needed to avoid this.
Lessons Learned: The unique feature of this initiative is the
development of HTA capacity at the local level—from the
“bottom up.” Users are empowered to adapt and change
the program according to their local context. Other elements
critical to the success of this project include education of partici-
pants (often one-on-one), appointment of HTA leaders in each
department, provision of starting documents, and a process
(retreats and interviews) to gather feedback for revision to the
documents. Challenges included slow buy-in time (approvals
needed from various levels of management), ﬁnding common
meeting times, resistance to change, and ensuring follow-
through.
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